Triple Negative Breast Cancer Clinical Trial Using Veliparib, Carboplatin, Paclitaxel, Doxorubicin and Cyclophosphamide

- The folks at AbbVie are studying the effects of Veliparib; Carboplatin; Paclitaxel; Doxorubicin; Cyclophosphamide on Triple Negative Breast Cancer in females ages 18 years and older. This clinical trial is slated to start January 2014 and is expected to end circa June 2016.

847-938-5570
Brian Oliver, BS
Overall Study Contact Info
StatusName Contact Phone
RecruitingBrian Oliver, BSbrian.oliver@abbvie.com847-938-5570

This study is officially titled, "A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC)."

Locations

Site Reference ID/Investigator# 116815

Lafayette, Indiana - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.